Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. (Q44498168)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

I L Antunes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

E Orsini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

F Ricci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

P L Tazzari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

P Pagliaro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

F Melchionda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Bertaina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

F Locatelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A M Martelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

6 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

1196-1206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The role of HOX genes in normal hematopoiesis and acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

MicroRNAs in acute leukemia: from biological players to clinical contributors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Critical roles of the PI3K/Akt signaling pathway in T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Side population analysis using a violet-excited cell-permeable DNA binding dye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

SP analysis may be used to identify cancer stem cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

The leukemic stem cell niche: current concepts and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Targeting nonclassical oncogenes for therapy in T-ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.369

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis

1 reference

12 December 2020

P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310736%20AND%20SRC:MED&resulttype=core&format=json